Soleno Therapeutics Raises $15M in Under Written Public Offering
REDWOOD CITY, Calif., April 01, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the closing of an underwritten public offering of 40,000,000 shares of its common stock at a public offering price of…Read More
Read MoreApexigen and Brookline Capital Acquisition Corp. Create Publicly Listed Immuno-oncology Company via SPAC
SAN CARLOS, CA, and NEW YORK, NY, March 18, 2022 – Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, and Brookline Capital Acquisition Corp. (Nasdaq: BCAC, BCACU, BCACW), a special purpose acquisition company (“SPAC”), today announced they have entered…Read More
Read MoreCitcon USA, LLC Engages FLG Partners
Citcon, a global all-in-one in-store, online, and mobile payment platform based in Silicon Valley has engaged FLG partner Bill Beyer.
Read MoreNXT-ID Appoints Key Executives : CFO Mark Archer and Rafael Saavedra as VP of Engineering
Feb. 17, 2022 /PRNewswire/ — NXT-ID, Inc. (NASDAQ: NXTD), provider of personal emergency response systems (PERS), health communications devices and IoT technology, today announces it has appointed FLG Partner Mark Archer as Chief Financial Officer, and Rafael Saavedra as VP of Engineering. The executives will join the leadership team and be responsible for…Read More
Read MoreCurevo Vaccine Announces $60 Million Series A Financing for new Shingles Vaccine
SEATTLE – February 10, 2022 – FLG client Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, has announced the closing of a $60 million Series A financing round. FLG partner Greg Curhan assisted as CFO….Read More
Read More
Recent News
